Description
Teveten HCT is a fixed-dose combination antihypertensive medication containing eprosartan mesylate, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. It is indicated for the treatment of hypertension in patients for whom combination therapy is appropriate. Eprosartan works by selectively blocking the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone-mediated volume expansion. Hydrochlorothiazide enhances this effect by promoting sodium and water excretion, reducing plasma volume and peripheral resistance. Together, they offer additive antihypertensive effects.
| F act Table |
| Formula | C23H24N2O4S (Eprosartan) + C7H8ClN3O4S2 (Hydrochlorothiazide) |
| License | US FDA |
| Bioavailability | Eprosartan: ~13%, Hydrochlorothiazide: 60–80% |
| Legal status | Prescription only (Rx) |
| Chemical Name | Eprosartan mesylate and Hydrochlorothiazide |
| Elimination half-life | Eprosartan: ~5–9 hours, Hydrochlorothiazide: 6–15 hours |
| Dosage (Strength) | 600 mg eprosartan / 12.5 mg hydrochlorothiazide (once daily) |
| Pregnancy | Contraindicated (especially 2nd/3rd trimester) |
| Brands | Teveten HCT |
| Protein binding | Eprosartan: ~98%, Hydrochlorothiazide: 40–70% |
| PubChem CID | Eprosartan: 65646, Hydrochlorothiazide: 3639 |
| MedlinePlus | a699006 (Hydrochlorothiazide) |
| ChEBI | Eprosartan: 50503, Hydrochlorothiazide: 5778 |
| ATC code | C09DA02 |
| DrugBank | Eprosartan: DB00876, Hydrochlorothiazide: DB00999 |
| KEGG | Eprosartan: D04031, Hydrochlorothiazide: D00340 |
| Routes of administration | Oral |
Directions
Teveten HCT is typically administered once daily, with or without food. The usual starting dose is one tablet containing 600 mg of eprosartan and 12.5 mg of hydrochlorothiazide. Dosage may be adjusted based on blood pressure response. It should not be used as initial therapy in patients with significant intravascular volume depletion. Patients should be monitored regularly for blood pressure, electrolytes, and renal function.
Ingredients
Each Teveten HCT tablet contains 600 mg of eprosartan mesylate and 12.5 mg of hydrochlorothiazide. Inactive ingredients may include lactose monohydrate, cellulose compounds, magnesium stearate, and other tablet excipients.
Contraindications
Teveten HCT is contraindicated in patients with known hypersensitivity to eprosartan, hydrochlorothiazide, sulfonamide-derived drugs, or any component of the formulation. It is also contraindicated in patients with anuria or severe renal impairment, and in those with hepatic impairment or hypercalcemia. Use is contraindicated during pregnancy, particularly in the second and third trimesters.
Cautions
Caution is advised in patients with renal or hepatic impairment, volume or salt depletion, diabetes mellitus, or gout. Thiazide diuretics may exacerbate electrolyte imbalances such as hypokalemia, hyponatremia, and hyperuricemia. Serum electrolytes and kidney function should be monitored regularly. Dual blockade of the renin-angiotensin system is not recommended. Use in combination with lithium, NSAIDs, or other antihypertensive agents requires careful monitoring.
Side Effects
Common side effects may include:
- Dizziness or lightheadedness
- Cough (less frequent than with ACE inhibitors)
- Hypokalemia or other electrolyte disturbances
- Increased uric acid or blood glucose levels
- Rare: angioedema, renal dysfunction, or photosensitivity reactions
IMPORTANT NOTE:
The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.
Product Code : 10364
Prescription Required
